1.88
3.30%
0.06
After Hours:
1.88
Akebia Therapeutics Inc stock is traded at $1.88, with a volume of 2.00M.
It is up +3.30% in the last 24 hours and up +14.63% over the past month.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
See More
Previous Close:
$1.82
Open:
$1.84
24h Volume:
2.00M
Relative Volume:
1.12
Market Cap:
$410.18M
Revenue:
$194.75M
Net Income/Loss:
$-51.26M
P/E Ratio:
-3.6154
EPS:
-0.52
Net Cash Flow:
$-23.38M
1W Performance:
+5.03%
1M Performance:
+14.63%
6M Performance:
+70.91%
1Y Performance:
+89.90%
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Name
Akebia Therapeutics Inc
Sector
Phone
617-871-2098
Address
245 FIRST STREET, CAMBRIDGE, MA
Compare AKBA with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
AKBA | 1.88 | 410.18M | 194.75M | -51.26M | -23.38M | -0.52 |
ZTS | 176.96 | 79.84B | 9.15B | 2.43B | 2.31B | 4.92 |
HLN | 9.65 | 43.63B | 14.26B | 1.55B | 0 | 0.3327 |
TAK | 13.38 | 42.42B | 30.27B | 1.93B | 3.45B | 0.444 |
TEVA | 17.12 | 19.40B | 16.77B | -959.00M | 1.37B | -2.00 |
VTRS | 13.37 | 15.96B | 15.05B | -883.30M | 1.89B | 1.53 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-31-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
Mar-31-22 | Downgrade | Mizuho | Buy → Neutral |
Mar-31-22 | Downgrade | Needham | Buy → Hold |
Mar-31-22 | Downgrade | Piper Sandler | Overweight → Neutral |
Mar-08-21 | Initiated | Cantor Fitzgerald | Overweight |
Jan-29-21 | Downgrade | JP Morgan | Neutral → Underweight |
Nov-14-19 | Reiterated | Needham | Buy |
Aug-06-19 | Reiterated | H.C. Wainwright | Buy |
Jul-11-19 | Reiterated | H.C. Wainwright | Buy |
May-02-19 | Initiated | JP Morgan | Overweight |
Mar-20-19 | Initiated | Citigroup | Neutral |
Sep-07-18 | Resumed | Morgan Stanley | Equal-Weight |
Aug-10-18 | Reiterated | Needham | Buy |
Jun-06-18 | Reiterated | H.C. Wainwright | Buy |
Dec-19-17 | Initiated | Piper Jaffray | Overweight |
Dec-07-17 | Initiated | BTIG Research | Buy |
Sep-15-17 | Initiated | RBC Capital Mkts | Sector Perform |
Jul-10-17 | Reiterated | H.C. Wainwright | Buy |
Apr-27-17 | Reiterated | H.C. Wainwright | Buy |
Apr-27-17 | Reiterated | Needham | Buy |
Dec-27-16 | Reiterated | H.C. Wainwright | Buy |
Dec-20-16 | Reiterated | JMP Securities | Mkt Outperform |
Nov-15-16 | Initiated | Aegis Capital | Buy |
Sep-29-16 | Initiated | Brean Capital | Buy |
Mar-16-16 | Reiterated | Needham | Buy |
Jan-21-16 | Initiated | Credit Suisse | Neutral |
View All
Akebia Therapeutics Inc Stock (AKBA) Latest News
Akebia Therapeutics to Present at the Jefferies London Healthcare Conference - GuruFocus.com
Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GuruFocus.com
Vadadustat Alternative Dosing Study Results Published in the Ame - GuruFocus.com
Akebia Therapeutics to Report Third Quarter 2024 Financial Resul - GuruFocus.com
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listi - GuruFocus.com
Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply C - GuruFocus.com
Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024 - GuruFocus.com
Q3 2024 Earnings: Hold Akebia Therapeutics (NASDAQ:AKBA) - Seeking Alpha
Akebia's FDA-Approved Vafseo Shows Promise in Key Dialysis Trial Results | AKBA Stock News - StockTitan
Akebia Therapeutics (NASDAQ:AKBA) Stock Rating Lowered by StockNews.com - Defense World
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q3 2024 Earnings Call Transcript - Insider Monkey
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.50 - Yahoo Finance
Earnings call: Akebia reports Q3 results, gears up for Vafseo launch - Investing.com Australia
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Price Is Right But Growth Is Lacking After Shares Rocket 41% - Simply Wall St
Akebia Therapeutics Inc (AKBA) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ... By GuruFocus - Investing.com Canada
Akebia Therapeutics Inc (AKBA) Q3 2024 Earnings Call Highlights: - GuruFocus.com
Akebia Therapeutics Inc (AKBA) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ... - Yahoo Finance
Akebia Therapeutics: Q3 Earnings Snapshot - CT Insider
Akebia Therapeutics Prepares for Vafseo Launch - TipRanks
Akebia Therapeutics Inc. (AKBA) Quarterly 10-Q Report - Quartzy
Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
SEC Form 10-Q filed by Akebia Therapeutics Inc. - Quantisnow
Here's Why You Should Consider Buying Akebia (AKBA) Stock - MSN
Akebia Therapeutics to present at upcoming investor conferences - MSN
Akebia Therapeutics (AKBA) Scheduled to Post Earnings on Thursday - MarketBeat
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Lelezard
Akebia Therapeutics Signs Commercial Supply Contract with Leadin - GuruFocus.com
Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights - citybiz
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Short Interest Down 6.0% in October - Defense World
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Short Interest Update - MarketBeat
EasyA x Polkadot Hackathon startup lands a spot at Y Combinator - Investing.com
Akebia Therapeutics (NASDAQ:AKBA) Stock Rating Reaffirmed by HC Wainwright - Defense World
Akebia stock climbs 8% on dialysis provider supply agreement - MSN
High Growth Tech Stocks to Watch in October 2024 - Simply Wall St
Akebia Therapeutics (NASDAQ:AKBA) shareholder returns have been respectable, earning 91% in 1 year - Simply Wall St
Akebia Therapeutics secures dialysis drug contract By Investing.com - Investing.com Australia
Akebia Therapeutics secures dialysis drug contract - Investing.com
Akebia Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow
Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis - Yahoo Finance
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class ActionAKBA - AsiaOne
Akebia Therapeutics extends supply agreement with STA Pharmaceutical - Investing.com
Akebia Therapeutics extends supply agreement with STA Pharmaceutical By Investing.com - Investing.com UK
Akebia Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement - Quantisnow
Akebia Therapeutics Inc Stock (AKBA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):